PROM1 and colorectal cancer: Using the marker CD133, a cancer stem cell marker that is overexpressed in colorectal cancer [41], they have developed antibody-conjugated Mit-A loaded nanoparticles (NPs) for colon targeted oral delivery and the treatment of colorectal cancer.